Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNG-IUS vs Megestrol Acetate for Atypical Endometrial Hyperplasia
NCT04897217Phase 3Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of avatrombopag in Endometrial Atypical Hyperplasia (EAH), sponsored by Wake Forest University Health Sciences. Planned start Jun 2023; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
Endometrial Atypical Hyperplasia (EAH)
Beyond the preview
Go deeper on NCT04897217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897217.